Lexicon Pharmaceuticals (LXRX) Total Current Liabilities (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Total Current Liabilities data on file, last reported at $9.9 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 91.06% year-over-year to $9.9 million in Q1 2026; TTM through Mar 2026 was $9.9 million, a 91.06% decrease from a year earlier, with the FY2025 full-year figure at $20.9 million, down 53.88% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $9.9 million, down from $20.9 million in the prior quarter.
• Over the last five years, Total Current Liabilities for LXRX reached as high as $110.7 million in Q1 2025 and fell as low as $9.9 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $30.5 million across 5 years, with a median of $23.4 million in 2024.
• Across the five-year window, Total Current Liabilities surged 373.07% in 2025 and plunged 91.06% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $23.2 million in 2022, then soared by 36.14% to $31.5 million in 2023, then soared by 43.43% to $45.2 million in 2024, then sank by 53.88% to $20.9 million in 2025, then plunged by 52.57% to $9.9 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $9.9 million in Q1 2026, $20.9 million in Q4 2025, and $21.7 million in Q3 2025.